Plaque psoriasis: no difference in drug survival for ixekizumab, secukinumab

Takeaway

• A comparative study found no statistically significant difference in drug survival between ixekizumab (Taltz) and secukinumab (Cosentyx) in patients with moderate to severe plaque psoriasis.

Why this matters

• Data on drug survival for biologics targeting interleukin 17 are scarce.

Key results

• 40.7% of patients who received secukinumab and 12.9% of patients who received ixekizumab were biologic-naive.
• Mean number of previous biologic treatments before initiation of secukinumab or ixekizumab were 1.3 and 3.6, respectively (P<.0001).
• 15.8% of patients treated with secukinumab and 12.9% of patients treated with ixekizumab discontinued therapy in the first 12 months (P=.075).
• 23.5% of biologic-naive patients treated with secukinumab and 0% of biologic-naive patients treated with ixekizumab discontinued therapy (P=.136).

Study design

• 430 patients with moderate to severe plaque psoriasis from the Dermbio database, 368 treated with secukinumab and 62 treated with ixekizumab, were analyzed for drug survival.
• Funding: None.

Limitations

• Only 62 patients treated with ixekizumab vs 368 treated with secukinumab.
• Although 0% of biologic-naive patients treated with ixekizumab discontinued therapy (vs 23.5% treated with secukinumab), only 12.9% of them were biologic-naive (vs40.7% treated with secukinumab).